Five Prime Therapeutics, Inc.
FPRX
FPRX was delisted on the 15th of April, 2021.
157 hedge funds and large institutions have $892M invested in Five Prime Therapeutics, Inc. in 2017 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 45 increasing their positions, 58 reducing their positions, and 40 closing their positions.
9% less funds holding
Funds holding: 172 → 157 (-15)
20% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 40
22% less repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 58
29% less capital invested
Capital invested by funds: $1.26B → $892M (-$364M)
33% less call options, than puts
Call options by funds: $1.7M | Put options by funds: $2.55M
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$96.4M |
| 2 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$32.1M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$30.4M |
| 4 |
Renaissance Technologies
New York
|
+$20.4M |
| 5 |
State Street
Boston,
Massachusetts
|
+$11.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$34.9M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$23.2M |
| 3 |
O
OppenheimerFunds
New York
|
-$16.8M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
-$15M |
| 5 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
-$12.8M |
FPRX Hedge Fund Activity: Q1 2017 in Review
157 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Five Prime Therapeutics, Inc. (FPRX) for Q1 2017, worth a combined $892M — down 29% from $1.26B a quarter earlier.
Sellers outnumbered buyers: 40 funds closed out of FPRX and 32 opened new positions — a net loss of 8 holders — while 58 trimmed existing stakes and 45 added.
The largest buyer was BlackRock, adding an estimated $96.4M. The largest seller was Acadian Asset Management, cutting an estimated $34.9M.
- 157 institutional investors held Five Prime Therapeutics, Inc. (FPRX) as of Q1 2017, down from 172 in Q4 2016.
- Funds reported $892M of Five Prime Therapeutics, Inc. stock for Q1 2017, down 29% quarter-over-quarter.
- 32 funds opened new Five Prime Therapeutics, Inc. positions in Q1 2017 and 40 closed out, a net change of -8 holders.
- The largest Five Prime Therapeutics, Inc. buyer in Q1 2017 was BlackRock, an estimated $96.4M added.
- The largest Five Prime Therapeutics, Inc. seller in Q1 2017 was Acadian Asset Management, an estimated $34.9M sold.
Based on aggregated 13F filings for Q1 2017.